Galectin-3 mediates the pulmonary arterial hypertension–induced right ventricular remodeling through interacting with NADPH oxidase 4

Journal of the American Society of Hypertension

Volumn 11, Issue 5, 2017, Pages 275-289.e2

  He, Jingni ^a   Li, Xiaohui ^b   Luo, Hui ^a   Li, Tangzhiming ^a   Zhao, Lin ^a   Qi, Qiangqiang ^a   Liu, Yuwei ^a   Yu, Zaixin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Galectin 3; NADPH oxidase 4; oxidative stress; right ventricular remodeling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; COLLAGEN TYPE 3; GALECTIN 3; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SMALL INTERFERING RNA; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA1; BIOLOGICAL MARKER; MONOCROTALINE; NOX4 PROTEIN, HUMAN; NOX4 PROTEIN, RAT; TGFB1 PROTEIN, RAT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HEART FIBROBLAST; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; IMMUNOFLUORESCENCE TEST; MALE; MONOCROTALINE-INDUCED PULMONARY HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PULMONARY HYPERTENSION; RAT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BLOOD; CARDIAC MUSCLE; CHEMICALLY INDUCED; COMPLICATION; CYTOLOGY; DISEASE MODEL; FIBROBLAST; FIBROSIS; GENE KNOCKDOWN; GENETICS; HEART VENTRICLE; METABOLISM; MIDDLE AGED; MYOFIBROBLAST; PATHOLOGY; PRIMARY CELL CULTURE; YOUNG ADULT;

ADULT; ANIMALS; BIOMARKERS; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FIBROSIS; GALECTIN 3; GENE KNOCKDOWN TECHNIQUES; HEART VENTRICLES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MONOCROTALINE; MYOCARDIUM; MYOFIBROBLASTS; NADPH OXIDASE 4; OXIDATIVE STRESS; PRIMARY CELL CULTURE; RATS; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; VENTRICULAR REMODELING; YOUNG ADULT;

EID: 85017512744     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2017.03.008     Document Type: Article

References (42)

1. Barst, R.J., Mcgoon, M.D., Elliott, C.G., Foreman, A.J., Miller, D.P., Ivy, D.D., Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 125:1 (2012), 113–122.
2. Chin, K.M., Kim, N.H., Rubin, L.J., The right ventricle in pulmonary hypertension[J]. Coron Artery Dis 16:1 (2005), 13–18.
3. Vonk-Noordegraaf, A., Haddad, F., Chin, K.M., Forfia, P.R., Kawut, S.M., Lumens, J., et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. Turk Kardiyol Dern Ars 42:Suppl 1 (2014), 29–44.
4. Gomez-Arroyo, J., Mizuno, S., Szczepanek, K., Van Tassell, B., Natarajan, R., dos Remedios, C.G., et al. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ Heart Fail 6:1 (2013), 136–144.
5. Davidson, P.J., Davis, M.J., Patterson, R.J., Ripoche, M.A., Poirier, F., Wang, J.L., Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 12:5 (2002), 329–337.
6. Hsu, D.K., Liu, F.T., Regulation of cellular homeostasis by galectins. Glycoconj J 19:7–9 (2004), 507–515.
7. Liu, F.T., Hsu, D.K., Zuberi, R.I., Kuwabara, I., Chi, E.Y., Henderson, W.R., Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 147:4 (1995), 1016–1028.
8. Suzuki, O., Abe, M., Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large B cell lymphoma. Oncol Rep 19:3 (2008), 743–748.
9. Yang, R.Y., Rabinovich, G.A., Liu, F.T., Galectins: structure, function and therapeutic potential. Expert Rev Mol Med, 10, 2008, e17.
10. de Boer, R.A., Voors, A.A., Muntendam, P., van Gilst, W.H., Veldhuisen, D.J., Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 11:9 (2009), 811–817.
11. Karayannis, G., Triposkiadis, F., Skoularigis, J., Georgoulias, P., Butler, J., Giamouzis, G., The emerging role of galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers. Curr Heart Fail Rep 10:4 (2013), 441–449.
12. Madrigal-Matute, J., Lindholt, J.S., Fernandez-Garcia, C.E., Benito-Martin, A., Burillo, E., Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc, 3(4), 2014, e000785.
13. Beltrami, M., Ruocco, G., Dastidar, A.G., Franci, B., Lucani, B., Aloia, E., et al. Additional value of galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. Clin Chim Acta 457 (2016), 99–105.
14. French, B., Wang, L., Ky, B., Brandimarto, J., Basuray, A., Fang, J.C., et al. Prognostic value of galectin-3 for adverse outcomes in chronic heart failure. J Card Fail 22:4 (2016), 256–262.
15. Gullestad, L., Ueland, T., Kjekshus, J., Nymo, S.H., Hulthe, J., Muntendam, P., et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J 164:6 (2012), 878–883.
16. Calvier, L., Legchenko, E., Grimm, L., Sallmon, H., Hatch, A., Plouffe, B.D., et al. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart 102:5 (2016), 390–396.
17. Bogaard, H.J., Abe, K., Vonk, N.A., Voelkel, N.F., The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 135:3 (2009), 794–804.
18. Rich, J.D., Pulmonary hypertension and the right ventricle-thinking outside the box (Third International Right Heart Failure Summit, part 1). Pulm Circ 4:4 (2014), 696–704.
19. Mallat, Z., Philip, I., Lebret, M., Chatel, D., Maclouf, J., Tedgui, A., Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 97:16 (1998), 1536–1539.
20. Byrne, J.A., Grieve, D.J., Bendall, J.K., Li, J.M., Gove, C., Lambeth, J.D., et al. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 93:9 (2003), 802–805.
21. Sun, Y., Zhang, J., Lu, L., Chen, S.S., Quinn, M.T., Weber, K.T., Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161:5 (2002), 1773–1781.
22. Kinugawa, S., Tsutsui, H., Hayashidani, S., Ide, T., Suematsu, N., Satoh, S., et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 87:5 (2000), 392–398.
23. Mcmullen, J.R., Sherwood, M.C., Tarnavski, O., Zhang, L., Dorfman, A.L., Shioi, T., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109:24 (2004), 3050–3055.
24. Kuroda, J., Ago, T., Matsushima, S., Zhai, P., Schneider, M.D., Sadoshima, J., NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A 107:35 (2010), 15565–15570.
25. Zhao, Q.D., Viswanadhapalli, S., Williams, P., Shi, Q., Tan, C., Yi, X., et al. NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFkappaB signaling pathways. Circulation 131:7 (2015), 643–655.
26. Barman, S.A., Chen, F., Su, Y., Dimitropoulou, C., Wang, Y., Catravas, T.D., et al. NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling. Arterioscler Thromb Vasc Biol 34:8 (2014), 1704–1715.
27. Stenmark, K.R., Meyrick, B., Galie, N., Mooi, W.J., McMurtry, I.F., Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297:6 (2009), L1013–L1032.
28. Fredenburgh, L.E., Liang, O.D., Macias, A.A., Polte, T.R., Liu, X., Riascos, D.F., et al. Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation 117:16 (2008), 2114–2122.
29. Pokharel, S., Rasoul, S., Roks, A.J., van Leeuwen, R.E., van Luyn, M.J., Deelman, L.E., et al. N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension 40:2 (2002), 155–161.
30. Weber, K.T., Sun, Y., Bhattacharya, S.K., Ahokas, R.A., Gerling, I.C., Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 10:1 (2013), 15–26.
31. Cucoranu, I., Clempus, R., Dikalova, A., Phelan, P.J., Ariyan, S., Dikalov, S., et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97:9 (2005), 900–907.
32. Fenster, B.E., Lasalvia, L., Schroeder, J.D., Smyser, J., Silveira, L.J., Buckner, J.K., et al. Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension. Heart Vessels 31 (2016), 939–946.
33. Zhang, M., Brewer, A.C., Schroder, K., Santos, C.X., Grieve, D.J., Wang, M., et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A 107:42 (2010), 18121–18126.
34. Ago, T., Kuroda, J., Pain, J., Fu, C., Li, H., Sadoshima, J., Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res 106:7 (2010), 1253–1264.
35. Matsushima, S., Kuroda, J., Ago, T., Zhai, P., Park, J.Y., Xie, L.H., et al. Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circ Res 112:4 (2013), 651–663.
36. Funck, R.C., Wilke, A., Rupp, H., Brilla, C.G., Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 432 (1997), 35–44.
37. Guo, S., Feng, Z., Galectin-3 mediates the effect of PDGF on pulmonary arterial hypertension. Int J Clin Exp Med 8:9 (2015), 15302–15307.
38. Lajiness, J.D., Conway, S.J., Origin, development, and differentiation of cardiac fibroblasts. J Mol Cell Cardiol 70 (2014), 2–8.
39. Porter, K.E., Turner, N.A., Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123:2 (2009), 255–278.
40. Ma, Y., de Castro, B.L., Toba, H., Tyer, R.P., Hall, M.E., Winniford, M.D., et al. Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch 466:6 (2014), 1113–1127.
41. Chapman, D., Weber, K.T., Eghbali, M., Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res 67:4 (1990), 787–794.
42. Rosenkranz, S., TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63:3 (2004), 423–432.